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compare overall hospital costs between the two cohorts, con-
trolling for differences in variable distribution. RESULTS: From
9234 patients who met the inclusion criteria, 4972 patients
(53.8%) were prescribed warfarin and 5727 (62.0%) were
females. Overall rate of secondary diagnosis of VTE was 0.08%
(seven of 9241 patients; two enoxaparin and ﬁve warfarin
patients). Apart from LOS (p = 0.8089), NSD (p = 0.2421), and
gender (p = 0.4223), distribution of age (p < 0.0001) and in-
hospital deaths (p = 0.0045) were found to be signiﬁcantly dif-
ferent between the two cohorts. Overall mean hospital costs 
were found to be different (p < 0.0001) ($11,723.3 for warfarin
patients versus $11,963.9 for enoxaparin patients), after con-
trolling for signiﬁcant differences. Enoxaparin patients incurred
higher Medical/Surgical supplies ($616.7) and drugs/pharmacy
($312.1) expenses, while warfarin patients incurred more on
Operating-and-Recovery rooms ($766.4), Medical/Surgical
acute units ($487.3), and Laboratory ($39.6). CONCLUSIONS:
Overall rate of secondary diagnosis of VTE is very low for ortho-
pedic patients given prophylaxis; however, warfarin prophylaxis
showed a higher rate. Enoxaparin demonstrated a better clinical
outcome, but warfarin was signiﬁcantly less expensive. Further
research is needed to reconcile the clinical versus ﬁnancial
outcome ﬁndings from these analyses.
ENDOCRINE DISORDERS
PEN1
COST SAVINGS ASSOCIATED WITH FINER DOSING
INCREMENTS THROUGH THE USE OF NORDITROPIN
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Fixed dosing increments in injectable devices may lead to poten-
tial inefﬁciencies such as overdosing in weight-based regimens.
Finer dosing increments can reduce product wastage and trans-
late into cost savings. OBJECTIVE: To compare overdosage and
wastage (therefore cost) due to Norditropin NordiFlex® 5mg 
to that of other somatropin (human growth hormone, rDNA
origin) delivery systems (Norditropin NordiPen® 5mg,
Genotropin® 5mg, Humatrope® 6mg, and Nutropin® 10mg)
in children. METHODS: Total recommended daily dose of
somatropin was calculated over a range of body weights and
weight-based (mg/kg) dosing regimens. Only body weights
resulting in a daily dose up to the maximum allowable dose for
each delivery system were considered. The amount of product
dispensed at each dose was determined based on dosing incre-
ments for each delivery system. Dosing increments for
Norditropin NordiFlex® were 0.025mg, compared to 0.05–0.2
mg for other delivery systems. The amount of somatropin admin-
istered by Norditropin NordiFlex® and associated annual costs
were compared with other somatropin delivery systems. Drug
costs were based on current wholesale acquisition costs (WAC).
RESULTS: At a daily dose of 0.030mg/kg, product wastage in
Norditropin NordiFlex® was 5.3%, 3.8%, 3.8%, and 1.8%
lower than Humatrope®, Nutropin®, Genotropin® and
Norditropin NordiPen®, respectively. The annual cost due to
Norditropin NordiFlex® was estimated at $14,580, and was
$811, $570, $390, and $265 lower than Humatrope®,
Nutropin®, Genotropin®, and Norditropin NordiPen®, respec-
tively. Greater savings (7.3%) were seen in lower body-weight
groups. At a higher daily dose of 0.043mg/kg, product wastage
(and corresponding annual cost) in Norditropin NordiFlex® was
6.1% ($1006), 4.2% ($684), 4.2% ($491), and 2.2% ($358)
lower than Humatrope®, Nutropin®, Genotropin®, and
Norditropin NordiPen® respectively. CONCLUSION: Com-
pared to other delivery systems, Norditropin NordiFlex®
reduces overdosage and wastage of growth hormone, conse-
quently resulting in meaningful cost savings.
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About 20,000 children in the US receive somatropin (human
growth hormone, rDNA origin) for the treatment of growth
hormone deﬁciency (GHD), with approximately 4000 new cases
annually. While the cost-effectiveness of somatropin for the treat-
ment of GHD has been assessed in the UK, to our knowledge 
no estimates for the US have been reported. OBJECTIVE: To
generate estimates of cost-effectiveness/utility of Norditropin® 
(r-DNA somatropin) in the treatment of GHD in children.
METHODS: A decision-analytic model of the epidemiology and
treatment of GHD in children was developed. Treatment of
GHD was assessed in two hypothetical cohorts compared to no
treatment–treatment with Norditropin® 0.030mg/kg/day from
ages ﬁve through 16 years, and treatment from ages three
through 18 years. Costs included those related to drug acquisi-
tion, endocrinologist consultations, and primary care ofﬁce
visits. Estimates of patient weight by age and sex were derived
from published literature, as was the proportion of patients
achieving normal height through Norditropin® treatment and
pre/post-treatment patient utilities. Cost-effectiveness/utility was
estimated over patients’ expected lifetimes, and was stated alter-
natively as discounted (3% per annum) US dollars per normal
height year (NHY) gained, and cost per quality adjusted life-year
(QALY) gained. Multivariate sensitivity analyses were conducted
to ensure robustness of the model. RESULTS: The cost-
effectiveness and cost-utility of treating children from ages ﬁve
through 16 years with Norditropin® was estimated at $8909 per
NHY gained and $36,955 per QALY gained, respectively. Treat-
ment of children from ages three through 18 years was estimated
to cost $9277 per NHY gained and $42,556 per QALY gained.
Findings were relatively insensitive to variation in most model
parameters. CONCLUSION: For both age cohorts, the cost-
effectiveness/utility of Norditropin® in the treatment of GHD
compares favorably to well-accepted threshold values. Thus,
Norditropin® represents excellent value for money for the treat-
ment of GHD in children.
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OBJECTIVE: To derive health status values (utilities) for the
Swedish population. METHODS: EQ-5D data were collected
through a mailing survey to a random sample (n = 2990) of the
Swedish population (response rate 65%: complete data on 1741
(49.4% males; mean age 48.4). The model was estimated using
the Jackknife method and multiple regression analysis. The full
sample was randomly divided into 10 parts of approximately the
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same size. As a ﬁrst step, regression analysis in the full sample
was performed, where VAS assessment (0–100) of actual health
state constituted the dependent variable and dichotomized (some
problem/considerable problem) answers on the ﬁve dimensions
the independent. After excluding outliers, (standardized [z-]
residuals <-2.5 or >2.5), ten pairs of analyses were performed,
excluding one part of the sample at the time. From the ﬁrst analy-
sis in each pair, outliers were excluded and the second analysis
was performed. The coefﬁcients gained in the second analysis
were used to calculate Jackknife estimates of “true” coefﬁcients.
RESULTS: The model estimated constant of 89.7 and coefﬁcients
for each dimension assessed as having “some problem” (self care:
-15.89; mobility: -10.30; usual activities: -9.52; depression: 
-7.87; pain/discomfort: -7.49) and for having “considerable
problem” with pain/discomfort: -6.00; usual activities: -8.09;
depression: -33.66 and on any of dimensions: -20.18. Interac-
tions did not increase explanatory value of the analysis. 
CONCLUSIONS: Based on this model, the most important
determinant of health status value (utility) for the Swedish pop-
ulation is depression, followed by problems with mobility and
self-care. Pain/discomfort is the least important, regardless of the
magnitude of the problems were assessed.
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POPULATION
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OBJECTIVES: To assess to what extent QoL results obtained
through a generic instrument (EQ-5D) correlate with those cap-
tured by a disease-sensitive measure (QoL-Assessment of Growth
Hormone Deﬁciency in Adults). METHODS: Data were col-
lected through a mailing survey to a random sample (n = 2990)
of the Swedish population. The questionnaire comprised EQ-5D
and QoL-AGHDA. QoL-AGHDA is a 25-item measure that
elicits yes/no responses to personal statements describing prob-
lems that characterize aspects of HrQoL in growth hormone deﬁ-
ciency. A high QoL-AGHDA score denotes poor HrQoL. EQ-5D
is a well-known and widely recognized generic instrument.
(EuroQoL Group, 1990). The response rate was 65% and com-
plete data on EQ-5D and QoL-AGHDA were obtained from
1665 (48.2% males; mean age 49.5, range 18–85 years) respon-
dents. RESULTS: For EQ-5D dimensions: 11% respondents
reported problems with mobility, 2% with self care, 9% usual
activities, 46% pain/discomfort and 30% anxiety/depression. All
results were weighted to represent the Swedish population proﬁle
with respect to age and gender. The mean EQ-5D VAS score was
80 (SD 17.3) and the mean QoL-AGHDA score was 3.9 (SD
4.8). There was a signiﬁcant correlation between QoL-AGHDA
scores and EQ-5D VAS (r = -0.56, p < 0.001). CONCLUSIONS:
These results show that there is strong correlation between
results generated by a disease-sensitive and a generic measure,
and thus suggest that using generic instruments for QoL assess-
ments in speciﬁc conditions yield reliable results that could be
employed for pharmacoeconomic evaluations.
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OBJECTIVES: Measuring the cost-effectiveness of interventions
for adult growth hormone deﬁciency (AGHD) requires estimates
of the beneﬁts. For the purposes of cost-utility analysis those ben-
eﬁts should be expressed as QALYs. Where primary outcomes
data are collected using condition-sensitive measures of health-
related quality of life (HrQoL) then recalibration is necessary.
This paper reports the use of EQ-5D as a mechanism for con-
verting such data into a useable QALY metric. METHODS:
QoL-AGHDA is a 25-item questionnaire designed for use in
AGHD. Yes/no responses are used to compute a summary index
with a high score denoting poor HrQoL. A total of 1000 indi-
viduals randomly selected from the UK Population Preference
Panel were sent a copy of QoL-AGHDA together with EQ-5D,
a widely used generic measure of HrQoL calibrated in terms of
TTO preference weights. Corresponding QoL-AGHDA data on
patients (n = 836) was made available from UK KIMS (Pﬁzer
International Metabolic Database). RESULTS: Completed
survey forms were received from 882 individuals (57% female,
median age 55). There was a high degree of correlation between
EQ-5D and QOL-AGHDA summary score (r = -0.529, p <
0.001). Age/gender standardised mean EQ-5D index scores were
computed for different categories of QoL-AGHDA score in the
general population survey. These were used as a lookup table to
provide estimates of EQ-5D for each patient in the KIMS dataset
according to their age/gender and QoL-AGHDA score. Within-
year QALY losses between the EQ-5D index for KIMS patients
and corresponding EQ-5D for the general population. Using 
age-speciﬁc prevalence data together with the relevant popula-
tion life expectancy tables, it was also possible to estimate poten-
tial lifetime QALY losses for GHD. CONCLUSIONS: AGHD
patients record lower levels of HrQoL than the general popula-
tion. This difference equates to a 0.15 QALY “loss” per annum
and a lifetime loss across all GHD patients of some 40,000
QALYs.
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There is conﬂicting evidence about whether reduced height
results in ill health. OBJECTIVE: The objective of this study was
to determine if there exists an association between height and
health-related utility (EQ5Dindex). METHODS: This was a retro-
spective study of two large health data sources that recorded
height and other anthropomorphic parameters along with the
EQ5Dindex. The ﬁrst a national survey in the general population
(English Health Survey, 1996), the second an ongoing study to
characterise outcome in hospital treated patients (the Health
Outcomes Data Repository [HODaR]). Both of these sources
had large numbers of observations, thus dealing with the wide
variability in factors leading to ill health potentially confound-
ing or masking any association. RESULTS: There was a direct
association between height and the EQ5Dindex. This association
was logarithmic; the gradient was more marked in shorter 
subjects. The association was signiﬁcant. On average, a 10cm
increase in height resulted in 0.01 more EQ5Dindex units in men
and 0.02 in women (standardized for age and ethnicity). This
association appeared to be independent of confounding factors
such as body mass, where shorter people had in all BMI cate-
gories lower health utility than taller people. An increase in
height from the ninth centile to the eighth equated to a utility
gain of 0.021 in men and 0.025 in women. A shift from the third
centile to the second equated to a utility gain of 0.007 in men
